|
Re: Lower LDL-C and Increased Type 2 Diabetes Risk
|
3
|
Resverlogix Corp.
|
Jun 03, 2020 09:59PM
|
|
Re: Lower LDL-C and Increased Type 2 Diabetes Risk - Bear
|
7
|
Resverlogix Corp.
|
Jun 06, 2020 01:24PM
|
|
Re: Management performance
|
10
|
Resverlogix Corp.
|
Apr 27, 2021 12:49PM
|
|
Re: Merck and Pfizer competition for a COVID 19 pill (Stat News)
|
7
|
Resverlogix Corp.
|
Apr 15, 2021 09:03AM
|
|
Re: National Kidney Foundation -Abstract: BOM
|
5
|
Resverlogix Corp.
|
Mar 30, 2020 02:46PM
|
|
Re: National Kidney Foundation -Abstract: BOM
|
9
|
Resverlogix Corp.
|
Mar 30, 2020 04:00PM
|
|
Re: Nature Article on the role of Endothelial Cells in COVID 19
|
8
|
Resverlogix Corp.
|
May 23, 2020 07:58PM
|
|
Re: Nature Article on the role of Endothelial Cells in COVID 19 - more stuff
|
9
|
Resverlogix Corp.
|
May 31, 2020 04:35PM
|
|
Re: Nature Article on the role of Endothelial Cells in COVID 19 - new article
|
8
|
Resverlogix Corp.
|
Jun 02, 2020 09:38PM
|
|
Re: New Presentation
|
2
|
BIOASIS TECHNOLOGIES INC
|
Nov 23, 2020 07:03PM
|
|
Re: New study in the Lancet regarding COVID 19 and blood clotting
|
2
|
Resverlogix Corp.
|
Jun 30, 2020 07:18PM
|
|
Re: New-Report of exempt distribution
|
10
|
Resverlogix Corp.
|
Jan 05, 2021 05:40PM
|
|
Re: Nine Months, 2021- Financials and MD&A on SEDAR
|
1
|
Resverlogix Corp.
|
Nov 13, 2021 02:34PM
|
|
Re: Not good for the potential of apabetalone as a Covid-19 therapy
|
2
|
Resverlogix Corp.
|
Dec 01, 2021 04:59PM
|
|
Re: Option #2 and Option #3 questions
|
1
|
Resverlogix Corp.
|
Oct 27, 2020 02:16PM
|
|
Re: Our own BKC on the webcast
|
5
|
Resverlogix Corp.
|
Feb 04, 2021 12:53PM
|
|
Re: PNAS
|
6
|
Resverlogix Corp.
|
Jan 01, 2021 04:15PM
|
|
Re: PNAS
|
4
|
Resverlogix Corp.
|
Jan 01, 2021 05:59PM
|
|
Re: PNAS - jbuffet
|
5
|
Resverlogix Corp.
|
Jan 02, 2021 01:33PM
|
|
Re: PNAS - jbuffet
|
4
|
Resverlogix Corp.
|
Jan 02, 2021 05:30PM
|
